Abstract
Multiple sclerosis (MS) is a complex autoimmune disease of the central nervous system. Diseasemodifying drugs licensed for MS treatment have been developed to reduce relapse rates and halt disease progression. The majority of current MS drugs involve regular, parenteral administration, affecting long-term adherence and thus reducing treatment efficacy. Over the last two decades great progress has been made towards developing new MS therapies with different modes of action and biologic effects. In particular, oral drugs have generated much interest because of their convenience and positive impact on medication adherence. Fingolimod was the first launched oral treatment for relapsing-remitting MS; recently, Teriflunomide and Dimethyl fumarate have also been approved as oral disease-modifying agents. In this review, we summarize and discuss the history, pharmacodynamics, efficacy, and safety of oral agents that have been approved or are under development for the selective treatment of MS.
Keywords: Multiple sclerosis, oral drugs, medication adherence, efficacy, safety.
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title:Oral Agents in Multiple Sclerosis
Volume: 14 Issue: 1
Author(s): L. Lorefice, G. Fenu, J. Frau, G.C. Coghe, M.G. Marrosu and E. Cocco
Affiliation:
Keywords: Multiple sclerosis, oral drugs, medication adherence, efficacy, safety.
Abstract: Multiple sclerosis (MS) is a complex autoimmune disease of the central nervous system. Diseasemodifying drugs licensed for MS treatment have been developed to reduce relapse rates and halt disease progression. The majority of current MS drugs involve regular, parenteral administration, affecting long-term adherence and thus reducing treatment efficacy. Over the last two decades great progress has been made towards developing new MS therapies with different modes of action and biologic effects. In particular, oral drugs have generated much interest because of their convenience and positive impact on medication adherence. Fingolimod was the first launched oral treatment for relapsing-remitting MS; recently, Teriflunomide and Dimethyl fumarate have also been approved as oral disease-modifying agents. In this review, we summarize and discuss the history, pharmacodynamics, efficacy, and safety of oral agents that have been approved or are under development for the selective treatment of MS.
Export Options
About this article
Cite this article as:
Lorefice L., Fenu G., Frau J., Coghe G.C., Marrosu M.G. and Cocco E., Oral Agents in Multiple Sclerosis, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2015; 14 (1) . https://dx.doi.org/10.2174/1871523014999150415130224
DOI https://dx.doi.org/10.2174/1871523014999150415130224 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthetic Glycolipid Ligands for Human iNKT Cells as Potential Therapeutic Agents for Immunotherapy
Current Medicinal Chemistry New Insights on the Possible Role of Mast Cells in Aspirin-Induced Asthma
Current Molecular Pharmacology siRNA Delivery Using Nanocarriers – An Efficient Tool for Gene Silencing
Current Gene Therapy Epigenetics in Ocular Diseases
Current Genomics Recent Advances for Cell / Gene Therapy in Rheumatoid Arthritis
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents MICA Gene and Relevance to Immune Responses in Organ Transplants and Inflammatory, Tumoral and Autoimmune Diseases
Current Immunology Reviews (Discontinued) Role of C1858T Polymorphism of Lymphoid Tyrosine Phosphatase in Egyptian Children and Adolescents with Type 1 Diabetes
Current Diabetes Reviews Vitiligo and Allergic Complications from Orthopaedic Joint Implants: The Role of Benzoyl Peroxide
Recent Patents on Inflammation & Allergy Drug Discovery The Role of Neutrophil Proteases in LPS-Induced Production of Regulatory Rheumatoid Factor that Suppresses Autoimmunity
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Advances in Improving Sub-Unit Vaccine Efficacy Using Cytokines as more Specific Immune Inducing Adjuvants
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Targeting T-Cell Adhesion Molecules for Drug Design
Current Pharmaceutical Design Implication of CD154/CD40 Interaction in Healthy and Autoimmune Responses
Current Immunology Reviews (Discontinued) Polymorphisms in Methotrexate Pathways: What Is Clinically Relevant, What Is Not, and What Is Promising
Current Drug Metabolism “Something is Wrong in the Ras Kingdom” - Evidence for the Involvement of p21Ras/MAP Kinase in Autoimmune Diseases
Current Rheumatology Reviews Methotrexate: A Drug of the Future in Ulcerative Colitis?
Current Drug Targets The Role of Chemokines in the Pathogenesis of Rheumatoid Arthritis
Current Rheumatology Reviews Mouse Models of Autoimmune Diseases
Current Drug Discovery Technologies Editorial [Hot Topic: Toll-Like Receptors and Innate Immunity: Potential Drug Targets for Treatment of Infectious, Inflammatory, and Autoimmune Diseases (Executive Editor: Emilio Jirillo)]
Current Pharmaceutical Design PROGRAMMED Cell Clearance: Molecular Mechanisms and Role in Autoimmune Disease, Chronic Inflammation, and Anti-Cancer Immune Responses
Current Immunology Reviews (Discontinued) Novel Superactive Leptin Antagonists and their Potential Therapeutic Applications
Current Pharmaceutical Design